Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more ...

Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an ...

Despite a flurry of executive actions and rhetoric about their supposed impact, thus far most favored nation policies have ...

President Trump, as soon as Thursday, may announce new tariffs on pharmaceutical and biotechnology companies that have yet to ...

A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

You have 16 companies that have entered into these voluntary deals with the White House HHS, and CMS. They are agreeing to ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

As Big Pharma companies consider foregoing European drug launches to avoid reducing drug prices in the U.S. in alignment with ...

By Michael Erman and Mariam Sunny March 19 (Reuters) - The U.S. government has begun engaging pharmaceutical companies as it works to build consensus around legislation to write President Donald Trump ...

Ahead of WTO's 14th ministerial meet, the USTR has called for a rethink of the MFN principle, citing changing economic ...

In my practice, I regularly sit with patients much like Anthony J. Petchkis from rural New Hampshire, who suddenly lost his ...